Calcineurin inhibitors of the setron family for the treatment of hearing loss
Disclosed is an inhibitor of calcineurin of the setron family for use for treating hearing loss in a subject in need thereof.
1. A method for treating sensorineural hearing loss in a subject affected with sensorineural hearing loss, comprising administering to said subject an inhibitor of calcineurin of the setron family selected from azasetron and pharmaceutically acceptable salts thereof, wherein sensorineural hearing loss is idiopathic sensorineural hearing loss, noise-induced sensorineural hearing loss, age-related sensorineural hearing loss or ototoxic drug-induced sensorineural hearing loss.
2. The method according to claim 1 , wherein said sensorineural hearing loss is a decrease in hearing of at least about 20 dB over at least three contiguous frequencies.
3. The method according to claim 1 , wherein said sensorineural hearing loss is total deafness.
4. The method according to claim 1 , wherein said sensorineural hearing loss is unilateral or bilateral.
5. The method according to claim 1 , wherein said sensorineural hearing loss is sudden sensorineural hearing loss.
6. The method according to claim 1 , wherein said sensorineural hearing loss is noise-induced sensorineural hearing loss or age-related sensorineural hearing loss.
7. The method according to claim 1 , wherein said subject is affected with sensorineural hearing loss since less than 7 days.
8. The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is systemically administered, topically administered or intra-tympanically injected.
9. The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is administered 1 to 3 times a day.
10. The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is administered for at least 30 days.
11. The method according to claim 1 , wherein the ototoxic drug inducing sensorineural hearing loss is selected from the group consisting of aminoglycosides, chemotherapeutic agents, loop diuretics, antimetabolites and salicylates.